Pfizer's Oncology Strategy Centers On Three Anchors To Steady The Ship

Ibrance, Xtandi and Bavencio are positioned as three anchor drugs with big market potential and opportunities for expansion, President-Worldwide R&D Mikael Dolsten said at a recent briefing at Pfizer's headquarters.